Taken together, our results suggest that disrupting the CXCL14/CCR7/STAT3 signaling axis, both in vitro and in vivo, enhances DNA damage and increases cisplatin sensitivity in bladder cancer. Here, CCR7 is linked to urinary bladder carcinoma.